Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
McKinsey
Express Scripts
McKesson
Johnson and Johnson

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

REMERON SOLTAB Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Remeron Soltab, and when can generic versions of Remeron Soltab launch?

Remeron Soltab is a drug marketed by Organon Usa Inc and is included in one NDA.

The generic ingredient in REMERON SOLTAB is mirtazapine. There are eighteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the mirtazapine profile page.

US ANDA Litigation and Generic Entry Outlook for Remeron Soltab

  Start Trial

A generic version of REMERON SOLTAB was approved as mirtazapine by TEVA on January 18th, 2020.

Drug patent expirations by year for REMERON SOLTAB
Drug Prices for REMERON SOLTAB

See drug prices for REMERON SOLTAB

Recent Clinical Trials for REMERON SOLTAB

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Teva Pharmaceuticals USAPhase 1

See all REMERON SOLTAB clinical trials

Recent Litigation for REMERON SOLTAB

Identify potential future generic entrants

District Court Litigation
Case NameDate
Purdue Pharmaceutical v. Actavis Elizabeth LLC2015-05-13
Cephalon Inc. v. Barr Pharmaceuticals Inc.2008-07-22
Cephalon Inc. v. Watson Pharmaceuticals Inc.2008-06-02

See all REMERON SOLTAB litigation

Synonyms for REMERON SOLTAB
(+/-)-12-Methyl-1,2,3,4,9,13b-hexahydro-2,4a,5-triaza-tribenzo[a,c,e]cycloheptene
(1)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine
(14bR)-2-methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine
1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine
1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c](2)benzazepine
1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine
1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine.
2-methyl-1,2,3,4,10,14b-hexahydrobenzo[c]pyrazino[1,2-a]pyrido[3,2-f]azepine
2-Methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine
2-methyl-1,2,3,4,9,13b-hexahydro-2,4a,5-triaza-tribenzo[a,c,e]cycloheptene
337M675
5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(15),8(13),9,11,16,18-hexaene
5-methyl-2,5,19-triazatetracyclo[13.4.0.0^{2,7}.0^{8,13}]nonadeca-1(19),8(13),9,11,15,17-hexaene
5-methyl-2,5,19-triazatetracyclo[13.4.0.0;{2,7}.0;{8,13}]nonadeca-1(19),8(13),9,11,15,17-hexaene
5-methyl-2,5,19-triazatetracyclo[13.4.0.0?,?.0?,??]nonadeca-1(19),8,10,12,15,17-hexaene
5-methyl-2,5,19-triazatetracyclo[13.4.0.0(2),.0,(1)(3)]nonadeca-1(19),8,10,12,15,17-hexaene
6-Azamianserin
61337-67-5
82601-27-2
85650-52-8
AB0014270
AB00698265_08
AB2000422
AC-15480
AC1L1HND
AC1Q3ZYM
AKOS005530681
AN-35645
AN-8319
ANW-42478
Avanza
Axit
Azamianserin
BBL009962
BCP14560
BCP22244
BCP9000930
BDBM50115644
BRD-A64977602-001-01-9
BRD-A64977602-001-04-3
C07570
CAS-61337-67-5
CCG-101154
CCG-220556
CHEBI:6950
CHEMBL654
CM0152
CPD000466347
CS-2398
CTK8B3409
D00563
DB00370
DSSTox_CID_3325
DSSTox_GSID_23325
DSSTox_RID_76979
DTXSID0023325
EINECS 288-060-6
EN300-49851
FT-0601544
FT-0628951
GTPL7241
HMS2052H03
HMS2233K03
HMS3268F21
HMS3370B05
HMS3374J01
HMS3394H03
HMS3657M13
HMS3713P13
HY-B0352
I01-1882
I06-0606
J10458
K532
KS-000010W5
KS-1086
L001294
LS-127703
LS-185067
M-130
M2151
MCULE-1174883554
ME-2040
Mepirzapin
Mepirzapine
Mepirzepine
methylBLAH
MFCD00865427
Mianserin, 6-Aza-; ORG 3770
Mirtabene
Mirtaz
Mirtazapin
Mirtazapina
Mirtazapina [INN-Spanish]
mirtazapine
Mirtazapine (JAN/USAN/INN)
Mirtazapine (Remeron, Avanza)
Mirtazapine [USAN:BAN:INN]
Mirtazapine [USAN:INN:BAN]
Mirtazapine [USAN:USP:INN:BAN]
Mirtazapine 1.0 mg/ml in Methanol
Mirtazapine for system suitability, European Pharmacopoeia (EP) Reference Standard
Mirtazapine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
Mirtazapine, >=98% (HPLC)
Mirtazapine, 98%
Mirtazapine, European Pharmacopoeia (EP) Reference Standard
Mirtazapine, United States Pharmacopeia (USP) Reference Standard
Mirtazapinum
Mirtazapinum [INN-Latin]
Mirtazepine
Mirtazipine
Mirtazon
MLS000759460
MLS001076676
MLS001424294
MLS006011449
MolPort-003-849-233
NC00404
NCGC00025346-01
NCGC00025346-02
NE42580
Norset
ORG 3770
Org-3770
PDSP1_001529
PDSP2_001513
Promyrtil
PubChem22104
PYR432
Pyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-
Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-
Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl- 85650-52-8
Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, (.+/-.)-
Reflex (TN)
Remergil
Remergon
Remeron
Remeron (TN)
Remeron, Avanza, Zispin
Remeron;Avanza
Rexer
RONZAEMNMFQXRA-UHFFFAOYSA-N
s2016
SAM001246659
SC-16155
SCHEMBL35408
Smilon
SMR000466347
SR-01000597530
SR-01000597530-1
SR-01000597530-4
ST24048108
STK711107
SW197784-4
Tox21_110965
TR-026749
VA11306
Z2327131613
Zispin
Paragraph IV (Patent) Challenges for REMERON SOLTAB
Tradename Dosage Ingredient NDA Submissiondate
REMERON SOLTAB TABLET, ORALLY DISINTEGRATING;ORAL mirtazapine 021208

US Patents and Regulatory Information for REMERON SOLTAB

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Organon Usa Inc REMERON SOLTAB mirtazapine TABLET, ORALLY DISINTEGRATING;ORAL 021208-001 Jan 12, 2001 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Organon Usa Inc REMERON SOLTAB mirtazapine TABLET, ORALLY DISINTEGRATING;ORAL 021208-002 Jan 12, 2001 AB RX Yes No   Start Trial   Start Trial   Start Trial
Organon Usa Inc REMERON SOLTAB mirtazapine TABLET, ORALLY DISINTEGRATING;ORAL 021208-003 Jan 12, 2001 AB RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for REMERON SOLTAB

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Organon Usa Inc REMERON SOLTAB mirtazapine TABLET, ORALLY DISINTEGRATING;ORAL 021208-003 Jan 12, 2001   Start Trial   Start Trial
Organon Usa Inc REMERON SOLTAB mirtazapine TABLET, ORALLY DISINTEGRATING;ORAL 021208-001 Jan 12, 2001   Start Trial   Start Trial
Organon Usa Inc REMERON SOLTAB mirtazapine TABLET, ORALLY DISINTEGRATING;ORAL 021208-001 Jan 12, 2001   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Boehringer Ingelheim
McKesson
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.